FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 310:15-18 January 5, 1984 Number 1 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We treated seven patients who had progressive hairy-cell leukemia with daily doses of 3 million units of partially pure alpha (leukocyte) interferon by the intramuscular route. Three patients had a complete remission, and four had a partial remission, according to strict criteria for a response. After treatment, bone-marrow aspirates showed an absence of leukemia cells in three patients and 5 per cent or fewer in three others. Normalization of subnormal peripheral-blood values occurred in six of six patients with anemia, in seven of seven with granulocytopenia, and in four of four with thrombocytopenia. Remissions have been maintained for over 6 to over 10 months. Alpha interferon appears to be highly effective in patients with hairy-cell leukemia.

This article has been cited by other articles:

• Golomb, H. M. (2008). Hairy Cell Leukemia: Treatment Successes in the Past 25 Years. JCO 26: 2607-2609 [Full Text]  
• Braiteh, F., Kurzrock, R. (2007). Uncommon tumors and exceptional therapies: paradox or paradigm?. Molecular Cancer Therapeutics 6: 1175-1179 [Abstract] [Full Text]  
• Wanko, S. O., de Castro, C. (2006). Hairy Cell Leukemia: An Elusive but Treatable Disease. The Oncologist 11: 780-789 [Abstract] [Full Text]  
• Ravandi, F., Jorgensen, J. L., O'Brien, S. M., Verstovsek, S., Koller, C. A., Faderl, S., Giles, F. J., Ferrajoli, A., Wierda, W. G., Odinga, S., Huang, X., Thomas, D. A., Freireich, E. J., Jones, D., Keating, M. J., Kantarjian, H. M. (2006). Eradication of minimal residual disease in hairy cell leukemia. Blood 107: 4658-4662 [Abstract] [Full Text]  
• Ravandi, F., O'Brien, S. (2005). Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis and Treatment. Mayo Clin Proc. 80: 1660-1674 [Abstract]  
• Thomas, D. A., O'Brien, S., Bueso-Ramos, C., Faderl, S., Keating, M. J., Giles, F. J., Cortes, J., Kantarjian, H. M. (2003). Rituximab in relapsed or refractory hairy cell leukemia. Blood 102: 3906-3911 [Abstract] [Full Text]  
• Davis, I. D., Jefford, M., Parente, P., Cebon, J. (2003). Rational approaches to human cancer immunotherapy. J. Leukoc. Biol. 73: 3-29 [Abstract] [Full Text]  
• Federico, M., Zinzani, P. L., Frassoldati, A., Vinceti, M., Mode, A., Annino, L., Chisesi, T., Pagnucco, G., Invernizzi, R., Spriano, M., Resegotti, L., Bendandi, M., Damasio, E. E. (2002). Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up. JCO 20: 638-646 [Abstract] [Full Text]  
• Kreitman, R. J., Wilson, W. H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D. J., Pastan, I. (2001). Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia. NEJM 345: 241-247 [Abstract] [Full Text]  
• Jonasch, E., Haluska, F. G. (2001). Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities. The Oncologist 6: 34-55 [Abstract] [Full Text]  
• Flinn, I. W., Kopecky, K. J., Foucar, M. K., Head, D., Bennett, J. M., Hutchison, R., Corbett, W., Cassileth, P., Habermann, T., Golomb, H., Rai, K., Eisenhauer, E., Appelbaum, F., Cheson, B., Grever, M. R. (2000). Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96: 2981-2986 [Abstract] [Full Text]  
• Shehata, M., Schwarzmeier, J. D., Nguyen, S. T., Hilgarth, M., Berger, R., Hubmann, R., Kickmaier, S., Decker, T. (2000). Reconstitution of Endogenous Interferon {{alpha}} by Recombinant Interferon in Hairy Cell Leukemia. Cancer Res. 60: 5420-5426 [Abstract] [Full Text]  
• Au, W. Y., Klasa, R. J., Gallagher, R., Le, N., Gascoyne, R. D., Connors, J. M. (1998). Second Malignancies in Patients With Hairy Cell Leukemia in British Columbia: A 20-Year Experience. Blood 92: 1160-1164 [Abstract] [Full Text]  
• Lauria, F., Bocchia, M., Marotta, G., Raspadori, D., Zinzani, P., Rondelli, D. (1997). Weekly Administration of 2-Chlorodeoxyadenosine in Patients With Hairy-Cell Leukemia: A New Treatment Schedule Effective and Safer in Preventing Infectious Complications. Blood 89: 1838-1839 [Full Text]  
• Binder, D., Fehr, J., Hengartner, H., Zinkernagel, R. M. (1997). Virus-induced Transient Bone Marrow Aplasia: Major Role of Interferon-{alpha}/{beta} during Acute Infection with the Noncytopathic Lymphocytic Choriomeningitis Virus. JEM 185: 517-530 [Abstract] [Full Text]  
• Gianni, M., Terao, M., Fortino, I., LiCalzi, M., Viggiano, V., Barbui, T., Rambaldi, A., Garattini, E. (1997). Stat1 Is Induced and Activated by All-Trans Retinoic Acid in Acute Promyelocytic Leukemia Cells. Blood 89: 1001-1012 [Abstract] [Full Text]  
• Muller, U, Steinhoff, U, Reis, L., Hemmi, S, Pavlovic, J, Zinkernagel, R., Aguet, M (1994). Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921 [Abstract]  
• Guyer, D. R., Adamis, A. P., Gragoudas, E. S., Folkman, J., Slakter, J. S., Yannuzzi, L. A. (1992). Systemic Antiangiogenic Therapy for Choroidal Neovascularization: What Is the Role of Interferon Alfa?. Arch Ophthalmol 110: 1383-1384 [Abstract]  
• Talpaz, M., Kantarjian, H., Kurzrock, R., Trujillo, J. M., Gutterman, J. U. (1991). Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia: Philadelphia Chromosome-Positive Patients. ANN INTERN MED 114: 532-538 [Abstract]  
• Glaspy, J. A., Baldwin, G. C., Robertson, P. A., Souza, L., Vincent, M., Ambersley, J., Golde, D. W. (1988). Therapy for Neutropenia in Hairy Cell Leukemia with Recombinant Human Granulocyte Colony-Stimulating Factor. ANN INTERN MED 109: 789-795 [Abstract]  
• Maurice, P. D. L, Bunker, C., Giles, F., Goldstone, A., Holton, J. (1988). Mycobacterium avium-intracellulare Infection Associated With Hairy-cell Leukemia. Arch Dermatol 124: 1545-1549 [Abstract]  
• O'DWYER, P. J., WAGNER, B., LEYLAND-JONES, B., WITTES, R. E., CHESON, B. D., HOTH, D. F. (1988). 2'-Deoxycoformycin (Pentostatin) for Lymphoid Malignancies: Rational Development of an Active New Drug. ANN INTERN MED 108: 733-743 [Abstract]  
• Coon, W. W. (1988). Splenectomy for Thrombocytopenia due to Secondary Hypersplenism. Arch Surg 123: 369-371 [Abstract]  
• Edwards, L. (1987). Interferon: Promises, Disappointments, and Tempered Optimism. Arch Dermatol 123: 743-744 [Abstract]  
• CHESON, B. D., MARTIN, A. (1987). Clinical Trials in Hairy Cell Leukemia: Current Status and Future Directions. ANN INTERN MED 106: 871-878 [Abstract]  
• FAUCI, A. S., ROSENBERG, S. A., SHERWIN, S. A., DINARELLO, C. A., LONGO, D. L., LANE, H. C. (1987). Immunomodulators in Clinical Medicine. ANN INTERN MED 106: 421-433 [Abstract]  
• FAHEY, J. L., SARNA, G., GALE, R. P., SEEGER, R. (1987). Immune Interventions in Disease. ANN INTERN MED 106: 257-274 [Abstract]  
• Yap, W., Teo, T., Tan, Y. (1986). An early event in the interferon-induced transmembrane signaling process. Science 234: 355-358 [Abstract]  
• Edwards, L., Levine, N., Weidner, M., Piepkorn, M., Smiles, K. (1986). Effect of Intralesional {alpha}2-Interferon on Actinic Keratoses. Arch Dermatol 122: 779-782 [Abstract]  
• CHAMPLIN, R., GALE, R. P., FOON, K. A., GOLDE, D. W. (1986). Chronic Leukemias: Oncogenes, Chromosomes, and Advances in Therapy. ANN INTERN MED 104: 671-688 [Abstract]  
• GALE, R. P., FOON, K. A. (1985). Chronic Lymphocytic Leukemia: Recent Advances in Biology and Treatment. ANN INTERN MED 103: 101-120 [Abstract]